Kenneth Kelley, co-founder and Chairman of XCMR, brings 40 years of entrepreneurial, venture capital, operational and technical biotechnology experience and advises on strategic direction, team building, financing, corporate partnering, and product development.
Mr. Kelley is also Chairman of the Board and mentor to the CEOs of five privately held biotechnology companies developing products and services in the infectious disease sector.
Previously, Mr. Kelley was a White House Presidential Executive Fellow and a Senior Advisor to the U.S. National Institutes of Health and the National Institute of Allergy and Infectious Diseases, Vaccine Research Center and to the Assistant Secretary of Preparedness and Response as well as an Advanced Leadership Fellow at Harvard University working on global preparedness for epidemics and pandemics.
As the Chief Executive Officer of privately-held PaxVax, Inc., Mr. Kelley brought several travel vaccines to the US market. As a venture capitalist with Latterell Venture Partners and K2 Bioventures, he made investments in early-stage biotechnology and medical device startups.
In 1994 Mr. Kelley founded IntraBiotics Pharmaceuticals served as CEO, Director and Chair of the Board of Directors for 8 years. Earlier, he was an Associate at Institutional Venture Partners (IVP), a consultant for McKinsey & Company, and a scientist at Integrated Genetics (acquired by Genzyme/Sanofi).
Mr. Kelley earned an MBA. from Stanford University and a BA in Biochemical Sciences from Harvard University and is a Fellow in the American Institute for Medical and Biological Engineering (AIMBE).
